Our clinical program translates our preclinical findings into a healthy aging immune restoration therapy for aged individuals. The goal of this program is to restore function to the aging hematopoietic and immune systems, promoting restoration of the aging body’s endogenous immune defense and surveillance capabilities. The proprietary clinical protocol that Rejenevie™ has developed harnesses the restorative ability of young blood stem and immune cells to improve stem and immune cell function in aging populations. Our initial study of five healthy aged patients who received the therapy demonstrated the approach to be safe for over 12 months post-treatment, and efficacious for a number of clinical parameters predictive of immune competence.

The clinical program follows stringent guidelines to ensure safety and the highest quality point-of-care.  The ideal candidate for the Rejenevie™ immune restoration therapy is a person over the age of 55, in good general health, with no history of blood-borne cancer.  The candidate will have peripheral blood collected prior to stem cell mobilization for baseline CBC, immune cell phenotyping and stimulation response.  After initial infusion, evaluation of patient response is made at 1, 3, 6, 9 and 12 months. Patients who respond to treatment and see improved immune function during follow-up will be re-assessed at 12 months post-treatment to determine restoration stability or regression.